Accueil   Diary - News   All news Valneva announces signing license agreement with China

Valneva announces signing license agreement with China

Valneva announces signing of an exclusive license agreement on EB66® Cell Line for Human and Veterinary Vaccines in People’s Republic of China

 

  • The partner Jianshun Biosciences Ltd is granted exclusive rights to commercialize the EB66® cell line in People’s Republic of China only
  • Valneva receives EUR 2.5 million upfront payment and is entitled to further annual license fees and royalties
  • China’s Human vaccine market reached nearly EUR 2 billion (RMB 13.7 billion) in 20121, with an average growth rate in the range of 16%-18% expected between 2014 and 2018
  • Valneva and Jianshun Biosciences Ltd see a significant business opportunity arising from the growth of the vaccine market and the technological shift of the Chinese vaccine manufacturing industry, which will benefit from the EB66® cell line as a modern cell-culture based production system.

 

 

Read the press release